Gaedicke et al., 2014 - Google Patents
Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cellsGaedicke et al., 2014
View HTML- Document ID
- 14600298006197397420
- Author
- Gaedicke S
- Braun F
- Prasad S
- Machein M
- Firat E
- Hettich M
- Gudihal R
- Zhu X
- Klingner K
- Schüler J
- Herold-Mende C
- Grosu A
- Behe M
- Weber W
- Mäcke H
- Niedermann G
- Publication year
- Publication venue
- Proceedings of the National Academy of Sciences
External Links
Snippet
A technology that visualizes tumor stem cells with clinically relevant tracers could have a broad impact on cancer diagnosis and treatment. The AC133 epitope of CD133 currently is one of the best-characterized tumor stem cell markers for many intra-and extracranial tumor …
- 102100017157 PROM1 0 title abstract description 161
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gaedicke et al. | Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells | |
| Luo et al. | Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry | |
| Weist et al. | PET of adoptively transferred chimeric antigen receptor T cells with 89Zr-oxine | |
| Niu et al. | PET of EGFR antibody distribution in head and neck squamous cell carcinoma models | |
| Houghton et al. | Site-specifically labeled CA19. 9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer | |
| Gainkam et al. | Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT | |
| Ruggiero et al. | Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes | |
| Chatterjee et al. | Noninvasive imaging of immune checkpoint ligand PD-L1 in tumors and metastases for guiding immunotherapy | |
| Watanabe et al. | Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? | |
| Cai et al. | Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody | |
| Carmon et al. | Application of immuno-PET in antibody–drug conjugate development | |
| Zhang et al. | Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody | |
| Tolmachev et al. | Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591 | |
| Keinänen et al. | Dual radionuclide theranostic pretargeting | |
| Warnders et al. | Biodistribution and PET imaging of labeled bispecific T cell–engaging antibody targeting EpCAM | |
| Paudyal et al. | Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu‐labeled bevacizumab in colorectal cancer xenografts | |
| Puttick et al. | EphA2 as a diagnostic imaging target in glioblastoma: a positron emission tomography/magnetic resonance imaging study | |
| Warnders et al. | Human epidermal growth factor receptor 3–specific tumor uptake and biodistribution of 89Zr-MSB0010853 visualized by real-time and noninvasive PET imaging | |
| Kang et al. | Noninvasive evaluation of CD20 expression using 64Cu-labeled F (ab′) 2 fragments of obinutuzumab in lymphoma | |
| Kwon et al. | 64Cu-labeled trastuzumab fab-PEG24-EGF radioimmunoconjugates bispecific for HER2 and EGFR: pharmacokinetics, biodistribution, and tumor imaging by PET in comparison to monospecific agents | |
| Terry et al. | Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts | |
| Hu et al. | Cerenkov luminescence tomography of aminopeptidase N (APN/CD13) expression in mice bearing HT1080 tumors | |
| Hrynchak et al. | Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies | |
| Li et al. | Molecular imaging of tumor-associated macrophages in cancer immunotherapy | |
| Chacko et al. | Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin |